Quanterix Bundle
Who Owns Quanterix?
Understanding Quanterix Corporation's ownership is key to grasping its market influence and strategic direction. Founded in 2007, this life sciences innovator is dedicated to transforming healthcare with its advanced digital immunoassay platforms.
Quanterix's proprietary Simoa technology allows for the detection of protein biomarkers at unprecedentedly low concentrations, crucial for early disease detection and personalized medicine. The company's impact is evident in its over 1,000 Simoa instruments installed and more than 3,200 scientific publications citing its work as of March 2025.
Quanterix Corporation is a publicly traded company, meaning its ownership is distributed among its shareholders. As of its latest filings, a significant portion of its shares are held by institutional investors, with individual investors also owning stakes. The company's financial performance in 2024 included total revenues of approximately $137.2 million, marking a 12% increase year-over-year, alongside a net loss of $38.5 million. Understanding the Quanterix BCG Matrix can offer insights into the strategic positioning of its various product lines within its portfolio.
Who Founded Quanterix?
Quanterix Corporation was established in 2007 by Dr. David Walt and Dr. Nick Naclerio, with David Okrongly initially leading as CEO. Dr. Walt's background as a Tufts University chemistry professor and founder of Illumina Inc. brought significant scientific and entrepreneurial expertise to the nascent company.
Founding Vision
The company's early mission centered on developing advanced assay kits for ultra-sensitive biomarker detection. This was driven by their proprietary Simoa technology.
Key Founders
Dr. David Walt, a distinguished professor and entrepreneur, co-founded Quanterix. Dr. Nick Naclerio also played a crucial role in the company's inception.
Initial Leadership
David Okrongly served as the first Chief Executive Officer of Quanterix. His leadership guided the company through its formative stages.
Technological Foundation
The core of Quanterix's early development was its Simoa technology. This platform was designed for highly sensitive detection of biomarkers.
Venture Capital Backing
Quanterix secured substantial early funding from prominent venture capital firms. This capital was essential for developing its innovative technology.
Series A Funding
The company raised $15 million in its Series A financing round. Key investors included ARCH Venture Partners and Bain Capital Ventures.
During its initial phase, Quanterix attracted significant investment, raising a total of $15 million in its Series A financing round. This crucial funding came from notable venture capital firms, including ARCH Venture Partners and Bain Capital Ventures, both of whom made their initial investments on August 25, 2008. While specific details regarding initial equity splits or shareholding percentages are not publicly disclosed, the backing from these early investors was vital for the development of the Simoa platform and the establishment of the company's operational framework. This early financial support laid the essential groundwork for Quanterix's subsequent expansion and eventual public offering, demonstrating strong confidence in the company's innovative approach. Understanding this early ownership structure is key to grasping the Growth Strategy of Quanterix.
Early Investment Landscape
The Series A funding round for Quanterix was a significant event, providing the necessary capital for technological advancement. The involvement of major venture capital firms underscored the potential perceived in the company's Simoa technology.
- Founders: Dr. David Walt, Dr. Nick Naclerio
- Initial CEO: David Okrongly
- Year Founded: 2007
- Series A Funding Amount: $15 million
- Key Series A Investors: ARCH Venture Partners, Bain Capital Ventures, Flagship Ventures
- Series A Investment Date for ARCH and Bain: August 25, 2008
Quanterix SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Quanterix’s Ownership Changed Over Time?
Quanterix Corporation's ownership trajectory shifted significantly with its public debut on the Nasdaq Global Market on December 7, 2017, under the ticker 'QTRX'. The initial public offering successfully raised $64.128 million by offering 4.275 million shares at $15.00 each, marking a pivotal moment in its ownership structure.
| Shareholder Type | Percentage of Shares | Number of Shares (approx.) |
| Institutional Owners | 76.5% | 32,467,000 |
| Insiders | 7.6% | 3,222,000 |
| General Public | 2.92% | 1,237,000 |
As of July 24, 2025, Quanterix Corporation's shareholder landscape is dominated by institutional investors, who collectively hold approximately 76.5% of the company's shares, totaling around 32,467,000 shares. This significant institutional backing, coupled with insider holdings of about 7.6% and public ownership of 2.92%, shapes the company's governance and strategic direction. Key institutional stakeholders include BlackRock, Inc., holding 7.32% (2,843,760 shares as of June 29, 2025), and The Vanguard Group, Inc., with a 6.50% stake (2,525,679 shares as of March 30, 2025). Other notable investors are Ameriprise Financial Inc., Portolan Capital Management, LLC, and Kent Lake PR LLC. These major shareholders, through their voting rights, can exert considerable influence on Quanterix's business strategies and future growth. The company's financial performance in 2024, with revenues reaching $137.2 million, a 12% increase year-over-year, alongside a net loss of $38.5 million, highlights the dynamic environment in which these ownership stakes operate.
Understanding Quanterix Ownership
The ownership structure of Quanterix is primarily characterized by substantial institutional investment, reflecting confidence in its market position. Understanding who owns Quanterix provides insight into its operational and strategic decision-making processes.
- Institutional investors hold the majority of Quanterix stock.
- Major shareholders include BlackRock and Vanguard.
- Insider ownership represents a significant portion of the company's shares.
- The company's ownership history is marked by its 2017 IPO.
- Recent financial performance impacts investor sentiment and Quanterix stock ownership.
Quanterix PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Quanterix’s Board?
The Board of Directors at Quanterix Corporation is composed of key individuals representing significant shareholder interests, company founders, and independent directors, ensuring diverse perspectives in governance. As of July 2025, the board includes Masoud Toloue (CEO and Director), Dr. David R. Walt (Co-Founder and Independent Director), William P. Donnelly (Independent Non-Employee Chairman), Jeffrey Elliott (Independent Director), Karen Flynn (Independent Director), Ivana Magovcevic-Liebisch (Independent Director), Paul Meister (Independent Director), Scott Mendel (Director), and Myla Lai-Goldman (Director).
| Director Name | Role | Affiliation |
|---|---|---|
| Masoud Toloue | Chief Executive Officer and Director | Management |
| Dr. David R. Walt | Co-Founder, Chairman of Scientific Advisory Board, and Independent Director | Founder/Independent |
| William P. Donnelly | Independent Non-Employee Chairman | Independent |
| Jeffrey Elliott | Independent Director | Independent |
| Karen Flynn | Independent Director | Independent |
| Ivana Magovcevic-Liebisch | Independent Director | Independent |
| Paul Meister | Independent Director | Independent |
| Scott Mendel | Director | Post-Acquisition |
| Myla Lai-Goldman | Director | Post-Acquisition |
Recent changes to the board include William P. Donnelly's appointment as Chairman of the Board on March 24, 2025, succeeding Martin D. Madaus. Following the acquisition of Akoya Biosciences, Scott Mendel and Myla Lai-Goldman joined the board, filling the vacancies left by Martin D. Madaus and Sarah Hlavinka. While specific details on dual-class shares are not publicly disclosed, the typical one-share-one-vote structure means institutional investors, who collectively held approximately 76.5% of shares as of June 2025, wield considerable voting power. The management team's average tenure is 2.4 years, and the board's average tenure is 2.5 years, indicating a relatively recent composition.
Understanding Quanterix Ownership and Governance
The structure of Quanterix's board and shareholder base significantly influences its strategic direction and operational decisions. Understanding who owns Quanterix provides insight into its governance and future trajectory.
- Institutional investors hold a substantial majority of Quanterix stock ownership.
- The board composition reflects a blend of founders, management, and independent directors.
- Recent board changes followed a significant acquisition, impacting Quanterix company structure ownership.
- The standard voting power typically aligns with a one-share-one-vote principle for publicly traded companies.
- Exploring Revenue Streams & Business Model of Quanterix can further illuminate the company's operational landscape.
Quanterix Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Quanterix’s Ownership Landscape?
Recent developments at Quanterix Corporation have significantly reshaped its ownership landscape over the past 3-5 years. A pivotal moment was the acquisition of Akoya Biosciences, Inc. on July 8, 2025, which aimed to establish an integrated biomarker measurement platform. This strategic move has altered the ownership percentages, with Quanterix shareholders now holding approximately 84% and Akoya shareholders holding about 16% of the combined entity.
| Event | Date | Impact on Ownership |
|---|---|---|
| Akoya Biosciences Acquisition | July 8, 2025 | Quanterix shareholders own 84%, Akoya shareholders own 16% of combined entity |
| Secondary Offering | February 2021 | Raised $200.0 million, increasing public float |
The company's financial trajectory also plays a role in its ownership trends. For the full year ended December 31, 2024, Quanterix reported preliminary unaudited revenue of approximately $137.2 million, a 12% increase year-over-year. Looking ahead, the company anticipates 2025 revenues, on a standalone basis, to be between $120 million and $130 million. Quanterix is targeting cash flow breakeven as a combined company in 2026, with an expected cash balance exceeding $100 million by the end of that year. These financial milestones are crucial for attracting and retaining investors, influencing Quanterix stock ownership.
Institutional Holdings
As of July 2025, 316 institutional owners collectively hold 42,438,810 shares. This indicates significant Quanterix major shareholders are institutions.
Insider Activity
Insider buying has been observed in the past three months. This suggests confidence from those within the company regarding its future prospects.
Board and Leadership Changes
William P. Donnelly was appointed Chairman of the Board in March 2025. New directors have also joined the board following the Akoya acquisition, influencing the Quanterix board of directors.
Ownership Trend Shifts
Institutional holdings saw a slight decrease from 86.98% to 86.95% in June 2025. Mutual funds also reduced their holdings from 64.80% to 63.99% in the same period, reflecting subtle shifts in Quanterix stock ownership.
Quanterix Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Quanterix Company?
- What is Competitive Landscape of Quanterix Company?
- What is Growth Strategy and Future Prospects of Quanterix Company?
- How Does Quanterix Company Work?
- What is Sales and Marketing Strategy of Quanterix Company?
- What are Mission Vision & Core Values of Quanterix Company?
- What is Customer Demographics and Target Market of Quanterix Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.